Three Clinical Studies Demonstrating Safety and Efficacy of Treatment for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) in Adults
This supplement is sponsored by Salix Pharmaceuticals.
In this supplement to GI & Hepatology news, Christine Frissora, MD, provides an overview of the burdens that patients with IBS-D experience. Three clinical efficacy and safety studies surrounding an FDA-approved treatment are also examined.
Topics include:
,- IBS-D diagnosis and treatment challenges
- The role of microbial imbalance and altered gut microbiota
- A treatment option for relief of IBS-D symptoms
XIFI.0273.USA.18

